



Index

Note: Page numbers of article titles are in **boldface** type.

A

- Abscess, pituitary, imaging of, 71
- Acidophilic stem cell adenoma, 27
- Acromegaly, in somatotroph adenoma, 43–45
 - after pituitary surgery, 134, 139–141
 - treatment of, 82–83, 139–141
- Adenohypophysis
 - anatomy of, 55–57
 - histogenesis of, 13
 - histology of, 25
 - hormones of, 17–20
 - vascular anatomy of, 14–15
- Adenohypophysitis, lymphocytic, imaging in, 72–73, 75
- Adenoma
 - acidophilic stem cell, 27
 - corticotropin-secreting. *See* Corticotroph adenoma.
 - gonadotropin-secreting. *See* Gonadotroph adenoma.
 - growth-hormone secreting. *See* Somatotroph adenoma.
 - mammotroph, 27–28
 - null cell, 34–35
 - plurihormonal, 28–29, 36
 - prolactin-secreting. *See* Prolactinoma.
 - somatotroph. *See* Somatotroph adenoma.
 - somatotroph-lactotroph, 27
 - thyrotroph. *See* Thyrotroph adenoma.
- Adrenalectomy, for Cushing's disease, 84
- Aneurysm, suprasellar, imaging of, 75–76
- Antidiuretic hormone (vasopressin), 21–22
 - deficiency of, after pituitary surgery, 124–126
 - inappropriate secretion of, after pituitary surgery, 126–129
 - regulation of, 123–124
 - replacement of, for diabetes insipidus, 126
- Arachnoid cyst, parasellar, imaging of, 63–64
- Astrocytoma, hypothalamic, imaging of, 65–66

B

- Bifrontal transbasal approach, to parasellar and suprasellar lesions, 114–119
- Bone disorders, in acromegaly, 43–44
- Bromocriptine
 - for acromegaly, 83
 - for hyperprolactinemia, for prolactinoma, 30, 81–82, 89–90, 143

C

- Cabergoline, for hyperprolactinemia, in prolactinoma, 81–82, 90, 143
- Carcinoma, pituitary, 36–37
- Cardiovascular disorders, in acromegaly, 44
- Cavernous sinuses
 - anatomy of, for pituitary surgery, 16–17
 - exposure of, in pituitary surgery, 102
- Cerebral salt wasting, after pituitary surgery, 128
- Chlorpropamide, for diabetes insipidus, 132
- Chondrosarcoma, clival, imaging of, 77
- Chordoma, clival, imaging of, 76–77
- Clivus
 - exposure of, in pituitary surgery, 101–102
 - neoplasms of, imaging of, 76–78
- Colorectal cancer, in acromegaly, 45
- Computed tomography
 - in craniopharyngioma, 62–63
 - in empty sella syndrome, 64–65
 - in hypothalamic astrocytoma, 65–66
 - in meningioma, 67
 - in pituitary abscess, 71
 - in pituitary adenomas, 59
 - in schwannoma, 70
 - in suprasellar aneurysm, 75
- Corticosteroids, for hypopituitarism, after pituitary surgery, 129
- Corticotroph(s), 25

Corticotroph adenoma
 Cushing's disease in, 45–48
 diagnosis of, 169
 long-term management of, 169
 outcome of, 169
 medical treatment of, 142
 pathology of, 31–32
 persistent, 141–142
 radiotherapy for, 142
 silent, 32
 surgical treatment of, 169
 persistent, 141–142
 postoperative endocrine management in, 130–131, 133–134
 preoperative management in, 94

Corticotropin, 18–19, 25
 adenomas secreting. *See* Corticotroph adenoma.
 deficiency of, after pituitary surgery, 132–133
 measurement of, in corticotroph adenoma, 47

Corticotropin-releasing hormone stimulation test, in corticotroph adenoma, 47

Cortisol
 excess of, in corticotroph adenoma, 31–32, 45–48
 medical treatment of, 83–84
 persistent, 141–142
 preoperative management of, in pituitary tumors, 94

Cranial nerve dysfunction, after pituitary radiotherapy, 162

Craniopharyngioma, imaging of, 61–63

Cushing, Harvey, transsphenoidal approach of, 2–5, 7

Cushing's disease
 after pituitary surgery, 130–131, 133–134
 in corticotroph adenoma, 31–32, 45–48
 long-term management of, 169
 outcome of, 169
 persistent, 141–142
 medical treatment of, 83–84

Cyst(s), parasellar, imaging of
 arachnoid, 63–64
 epidermoid, 64
 Rathke's cleft, 63

D

Desmopressin (DDAVP), for diabetes insipidus, after pituitary surgery, 126, 132

Dexamethasone suppression test, in corticotroph adenoma, 47

Diabetes insipidus, after pituitary surgery, 124–126, 132

Diaphragma sellae, anatomy of, 16

Dopamine agonists
 for gonadotroph adenoma, 84
 for prolactinoma, 30–31, 81–82, 89–90, 143

Dott, Norman, transsphenoidal approach of, 5–7

E

Empty sella syndrome, 16, 64–65

Endocrinopathies, in pituitary tumors. *See* Pituitary tumors, endocrinopathies in.

Endonasal transsphenoidal approach, to pituitary tumors, 99–100
 lateral (Hirsch), 1–2

Endoscope-assisted transsphenoid approach, to pituitary tumors, 104–105

Epidermoid cyst, parasellar, imaging of, 64

Estrogen, for persistent prolactinoma, 142

F

Fluid restriction, in antidiuretic hormone inappropriate secretion, 128–129

Follicle stimulating hormone, 19, 25–26
 excess of, in gonadotroph adenoma, 34, 42–43, 84

Frontotemporal transcavernous approaches, to parasellar and suprasellar lesions, 109–121
 bifrontal transbasal, 114–119
 orbitozygomatic, 109–114
 pterional, 109–111
 supraorbital, 119–121
 transzygomatic, 109–111

Furosemide, for antidiuretic hormone inappropriate secretion, 129

G

Gamma knife radiosurgery
 for pituitary tumors, 156–161
 for somatotroph adenoma, 83

Germinoma, parasellar, imaging of, 71

Glioma, parasellar, after pituitary radiotherapy, 162

Gonadotroph(s), 25–26

Gonadotroph adenoma
 diagnosis of, 42–43
 endocrinopathy in, 42–43
 imaging of, 43
 medical treatment of, 84
 pathology of, 34

Gonadotropins, 19, 25–26
 adenoma secreting. *See* Gonadotroph adenoma.
 deficiency of, after pituitary surgery, 132–133

Graves' disease, in thyrotroph adenoma, 49

Growth hormone, 19–20, 25
 deficiency of, after pituitary surgery, 133
 pituitary tumors secreting. *See* Somatotroph adenoma.

Growth hormone-releasing hormone, 20

Guiot, Gerard, transsphenoidal approach of, 6, 8

H

Hardy, Jules, transsphenoidal approach of, 8–10

Hemangiopericytoma, parasellar, imaging of, 68–70

Hemianopsia, bitemporal, in prolactinoma, 29

Hirsch, Oscar, transsphenoidal approach of, 1–2

Histiocytosis X, of pituitary, 72, 74

Hormones, pituitary, 17–22, 25–26. *See also specific hormones.*
 abnormalities of. *See* Pituitary tumors, endocrinopathies in.

Hydrocortisone, for hypopituitarism, after pituitary surgery, 129

Hypercortisolemia, in corticotroph adenoma, 31–32, 45–48
 medical treatment of, 83–84
 persistent, 141–142

Hypernatremia, after pituitary surgery, 124–126

Hyperprolactinemia
 in acromegaly, 44
 in prolactinoma, 29–31, 41–42
 medical treatment of, 81–82
 persistent, 142–143

Hyperthyroidism, in thyrotroph adenoma, 48–50

Hypocortisolism, after pituitary surgery, 129–130

Hypogonadism

in gonadotroph adenoma, 42
 in prolactinoma, 81–82

Hyponatremia, after pituitary surgery, 126–129

Hypophyseal arteries, anatomy of, 14–15

Hypophysectomy, in persistent acromegaly, 140

Hypophysis. *See* Pituitary gland; Pituitary tumors.

Hypopituitarism
 after pituitary surgery, 129–130
 in gonadotroph adenoma, 42
 in somatotroph adenoma, 44

Hypothalamus
 astrocytoma of, imaging of, 65–66
 dysfunction of, after pituitary radiotherapy, 161–162

I

Inferior petrosal sinus sampling, in corticotroph adenoma, 47–48

Infundibulum, in pituitary embryogenesis, 11–12

Insulin-like growth factor-1, in somatotroph adenoma, 139–141

Insulin resistance, in acromegaly, 44

Intermediate lobe, pituitary, physiology of, 20–21

K

Ketoconazole, for Cushing's disease, 83–84, 142

L

Lactotroph(s), 25. *See also* Prolactin; Prolactinoma.

Lanreotide
 for somatotroph adenoma, 83, 140
 for thyrotroph adenoma, 84

Linear accelerator-based radiosurgery, for pituitary tumors, 155–156

Luteinizing hormone, 19, 25–26
 excess of, in gonadotroph adenoma, 34, 42–43, 84

Lymphocytic adenohypophysitis, imaging in, 72–73, 75

Lymphoma, clival, imaging of, 78

M

Macroadenomas, pituitary, imaging of, 59–60

Magnetic resonance imaging
 in arachnoid cyst, 64
 in craniopharyngioma, 63
 in empty sella syndrome, 64–65
 in epidermoid cyst, 64
 in germinoma, 71
 in hemangiopericytoma, 69–70
 in histiocytosis, 74
 in hypothalamic astrocytoma, 66
 in lymphocytic adenohypophysitis, 73, 75
 in meningioma, 67–68
 in pituitary abscess, 71
 in pituitary histiocytosis X, 72
 in pituitary tuberculosis, 71
 in pituitary tumors, 57–61, 94
 corticotroph, 47
 for radiotherapy planning, 151–152
 for stereotactic radiosurgery, 160
 gonadotroph, 43
 preoperative, 94
 prolactinoma, 42
 in Rathke's cleft cyst, 63
 in schwannoma, 70
 in suprasellar aneurysm, 76

Mammomatotroph adenoma, 27–28

Melanotropins, 20–21

Meningioma, parasellar, imaging of, 67–68

Metastasis
 to clivus, imaging of, 78
 to pituitary, imaging of, 71

Metyrapone, for Cushing's disease, 83–84

Microadenomas, pituitary
 imaging of, 59
 surgical treatment of, **89–92**

Midnight plasma cortisol measurement, in
 corticotroph adenoma, 47

Mitotane, for Cushing's disease, 142

N

Nelson's syndrome, in corticotroph adenoma, 31–32

Neurohypophysis
 anatomy of, 55–56
 histology of, 21
 hormones of, 21–22
 vascular anatomy of, 15

Nonfunctioning or nonsecreting pituitary tumors.
See Pituitary tumors, nonfunctioning.

Nonsteroidal anti-inflammatory drugs, for
 diabetes insipidus, 132

Nose, pituitary surgical approach through, 1–2,
 99–100

Null cell adenoma, pathology of, 34–35

O

Ocreotide
 for gonadotroph adenoma, 84
 for somatotroph adenoma, 83, 140
 for thyrotroph adenoma, 84

Oncocytoma, pituitary, pathology of, 35

Optic chiasm, anatomy of, pituitary surgery
 and, 17

Optic nerve, anatomy of, pituitary surgery
 and, 17

Orbitozygomatic approach, to parasellar and
 suprasellar lesions, 109–114

Oxytocin, 21–22

P

Parasellar and suprasellar lesions. *See also*
 Pituitary tumors.
 anatomic considerations in, 16–17, 57
 imaging of
 anatomic considerations in, 55–57
 aneurysm, 75–76
 arachnoid cyst, 63–64
 clivus neoplasms, 76–78
 craniopharyngioma, 61–63
 empty sella, 64–65
 epidermoid cyst, 64
 germinoma, 71
 hemangiopericytoma, 68–70
 hypothalamic astrocytoma, 65–66
 meningioma, 67–68
 Rathke's cleft cyst, 63
 schwannoma, 70
 surgical treatment of
 bifrontal transbasal approach to, 114–119
 frontotemporal transcavernous approaches
 to, 109–121
 orbitozygomatic approach to, 109–114
 pterional approach to, 109–111
 supraorbital approach to, 119–121
 transcranial approaches to, **109–122**
 transzygomatic approach to, 109–111

Pegvisomant, for acromegaly, 83, 140

Pergolide, for prolactinoma, 81–82, 143

Pituitary fossa, anatomy of, 15–16

Pituitary gland

abscess of, imaging in, 71

anatomy of, 55–57

dysfunction of, after pituitary radiotherapy, 161–162

histiocytosis of, imaging in, 72, 74

histogenesis of, 13

histology of, 25–26

hormones of, 17–22, 25–26. *See also specific hormones.*

abnormalities of. *See* Pituitary tumors, endocrinopathies in.

hyperplasia of, imaging in, 61

imaging of, 55–57. *See also* Pituitary tumors, imaging of.

abscess, 71

adenomas, 57–61

histiocytosis X, 72, 74

lymphocytic adenohypophysitis, 72–73, 75

sarcoidosis, 71

techniques for, 57

tuberculosis, 71

versus hyperplasia, 61

lymphocytic adenohypophysitis of, 72–73, 75

metastasis to, imaging in, 71

sarcoidosis of, imaging in, 71

tuberculosis of, imaging in, 71

tumors of. *See* Pituitary tumors.

Pituitary tumors

anatomic considerations in, **11–23**, 55–57

embryologic, 11–13

gross, 13–14

surgical, 15–17

vascular, 14–15

carcinoma, pathology of, 36–37

classification of, 25–26

corticotropin-secreting. *See* Corticotroph adenoma.

endocrinopathies in, **41–54**

acromegaly, 43–45, 82–83, 134, 139–141

Cushing's disease. *See* Cushing's disease, in corticotroph adenoma.

gonadotrophin abnormalities, 42–43

hyperprolactinemia, 29–31, 41–42, 81–82, 142–143

hyperthyroidism, 48–50

postoperative management of, **123–138**

acromegaly, 131, 133

antidiuretic hormone abnormalities, 123–129, 132

Cushing's disease, 130–131, 133–134

hypopituitarism, 129–130

in nonfunctioning tumors, 132–133

in prolactinoma, 131, 134

in somatotroph adenoma, 131, 133

in thyrotroph adenoma, 131–132, 134

gonadotropin-secreting. *See* Gonadotroph adenoma.

growth-hormone secreting. *See* Somatotroph adenoma.

imaging of

adenomas, 57–61

corticotroph, 47

gonadotroph, 43

metastasis, 71

preoperative, 94

prolactinoma, 42

long-term management of, **167–171**

macroadenomas, 59–60

malignant, after radiotherapy, 162

medical treatment of, **81–87**, 140–144

in long-term management, **167–171**

in persistent endocrine activity, 140–144

metastatic, imaging of, 71

microadenomas, 59, **89–92**

nonfunctioning

classification of, 169–170

long-term management of, 169–170

pathology of, 34–35

postoperative endocrine management in, 132–133

null cell adenoma, 34–35

oncocyoma, 34–35

outcome of, **167–171**

pathology of, **25–29**

carcinoma, 36–37

corticotroph adenoma, 31–32

gonadotroph adenoma, 34

nonfunctioning, 34–35

plurihormonal, 36

prolactinoma, 29–31

somatotroph adenoma, 26–29

thyrotroph adenoma, 32–33

versus normal pituitary, 25–26

persistent functional, management of, **139–145**

physiologic considerations in, 17–22

anterior lobe, 17–20

intermediate lobe, 20–21

posterior, 21–22

plurihormonal, 28–29, 36

prolactin-secreting. *See* Prolactinoma.

radiotherapy for. *See* Radiotherapy, for pituitary tumors; Stereotactic radiosurgery, for pituitary tumors.

surgical treatment of, **93–107**

Pituitary tumors (*continued*)

bifrontal transbasal approach to, 114–119
frontotemporal transcavernous approaches to, 109–121

in long-term management, 167–170
in persistent endocrine activity, 139–143
in suprasellar and parasellar region,

109–122

indications for, 93–94

lateral endonasal approach (Hirsch) to, 1–2

microprolactinomas, **89–92**

nonfunctioning, 170

orbitozygomatic approach to, 109–114

postoperative endocrine management in,

123–145

preoperative considerations in, 94

pterional approach to, 109–111

stereotactic radiosurgery. *See* Stereotactic radiosurgery.

sublabial transsphenoidal approach (Cushing) to, 2–4, 7

supraorbital approach to, 119–121

transcranial approaches to, 4–5, 103–104,

109–122

transsphenoidal approach to. *See*

Transsphenoidal approach.

transzygomatic approach to, 109–111

thyrotropin-secreting. *See* Thyrotroph adenoma.

treatment of

long-term, **167–171**

medical. *See* Pituitary tumors, medical treatment of.

microprolactinomas, **89–92**

persistent functional, **139–145**

radiotherapy in. *See* Radiotherapy, for pituitary tumors.

surgical. *See* Pituitary tumors, surgical treatment of.

transsphenoidal approach to. *See*

Transsphenoidal approach.

versus hyperplasia, 61

Plasmacytoma, clival, imaging of, 78

Plurihormonal adenoma, 28–29, 36

Polyneuropathy, in acromegaly, 44

Polyuria, in diabetes insipidus, after pituitary surgery, 125

Pregnancy, in acromegaly, 45

Prolactin, 20, 25

excess of. *See* Hyperprolactinemia.

in acidophilic stem cell adenoma, 27

in mammosomatotroph adenoma, 27–28

in somatotroph-lactotroph adenoma, 27

Prolactinoma

diagnosis of, 42–43

differential diagnosis of, 42–43

endocrinopathy in, 42

hyperprolactinemia in, 29–31, 41–42

persistent, 142–143

treatment of, 81–82

imaging of, 42, 58

long-term management of, 167–168

medical treatment of, 81–82, 89–90, 143, 167

outcome of, 167–168

pathology of, 29–31

persistent, 142–143

radiotherapy for, 142

surgical treatment of, 90, 143

micro-, **89–92**

outcome of, 167–168

postoperative endocrine management in, 131, 134

Proopiomelanocortin, 17, 20

Prostate hyperplasia, in acromegaly, 44

Proton beam radiosurgery, for pituitary tumors, 154–155

Psychologic disorders, in acromegaly, 45

Pterional approach

to parasellar and suprasellar lesions, 109–111

to pituitary tumors, 104

Q

Quinagolide, for hyperprolactinemia, 81–82

R

Radiotherapy, for pituitary tumors, **147–166**

conformal techniques for, 151–153

conventional techniques for, 149–151

corticotroph adenoma, 142

efficacy of, 147–149

external beam, 147–153, 161–162

in long-term management, **167–171**

in persistent endocrine activity, 140–144

nonfunctioning, 170

planning for, 149

prolactinoma, 143

somatotroph adenoma, 140–141, 168

stereotactic. *See* Stereotactic radiosurgery.

thyrotroph adenoma, 144

toxicity of, 148, 161–163

Rathke's cleft cyst, imaging of, 63

Rathke's pouch, in pituitary embryogenesis, 11–12

Respiratory disorders, in acromegaly, 44

S

Saline solution, for antidiuretic hormone inappropriate secretion, 128–129

Salt wasting, cerebral, after pituitary surgery, 128

Sandostatin

for somatotroph adenoma, 83, 140

for thyrotroph adenoma, 144

Sarcoidosis, of pituitary, 71

Schwannoma, parasellar, imaging of, 70

Scintigraphy, in somatotroph adenoma, 45

Sellar tumors, anatomic considerations in, 15–16, 57

Skin disorders, in acromegaly, 44

Skull base, anterior, exposure of, in pituitary surgery, 100–101

Somatostatin analogues

for somatotroph adenoma, 83, 140

for thyrotroph adenoma, 84, 144

Somatotroph(s), 25

Somatotroph adenoma

acromegaly in, 43–45

after pituitary surgery, 134, 139–141

long-term management of, 168–169

medical treatment of, 82–83

persistent, 139–141

densely granulated, 26–27

diagnosis of, 45

long-term management of, 168–169

medical treatment of, 140, 168

mixed cell, 27–29

outcome of, 168–169

pathology of, 26–29

persistent, 139–141

radiotherapy for, 140–141

sparsely granulated, 27

surgical treatment of

persistent, 139–140

postoperative endocrine management in, 131, 134

Somatotroph-lactotroph adenoma, 27

Stereotactic radiosurgery, for pituitary tumors, 153–161

gamma knife, 83, 156–161

historical view of, 6, 8

linear accelerator-based, 155–156

nonfunctioning, 170

prolactinoma, 90–91

proton beam, 154–155

somatotroph adenoma, 141

toxicity of, 162–163

Stroke, after pituitary radiotherapy, 162–163

Subfrontal approach, anterior, to pituitary tumors, 104

Sublabial transsphenoidal approach, to pituitary tumors, 2–4, 7, 94–99

Supraorbital approach, to parasellar and suprasellar lesions, 119–121

Suprasellar tumors. *See* Parasellar and suprasellar lesions.

Syndrome of inappropriate antidiuretic hormone secretion, after pituitary surgery, 126–129

T

Thiazide diuretics, for diabetes insipidus, 132

Thirst, in diabetes insipidus, after pituitary surgery, 125

Thyroid stimulating hormone, 19, 25

pituitary tumors secreting. *See* Thyrotroph adenoma.

preoperative management of, in pituitary tumors, 94

Thyrotroph(s), 25

Thyrotroph adenoma

diagnosis of, 49–50

differential diagnosis of, 49–50

hyperthyroidism in, 48–50

medical treatment of, 84, 143–144

pathology of, 32–33

radiotherapy for, 144

surgical treatment of

persistent, 143

postoperative endocrine management in, 131–132, 134

preoperative management in, 94

Transcranial approaches

to parasellar and suprasellar lesions, **109–122**
to pituitary tumors, 4–5, 93–94, 103–104

Transmaxillary transsphenoidal approach, 102–103

Transsphenoidal approach, to pituitary tumors, 93–103

Transsphenoidal approach (*continued*)

- anterior skull base exposure in,
100–101
- cavernous sinus exposure in, 102
- clivus exposure in, 101–102
- combined transmaxillary, 102–103
- Cushing technique for, 2–5, 7
- Dott technique for, 5–7
- endonasal, 1–2, 99–100
- endoscope-assisted, 104–105
- extended, 100–102
- Guiot technique for, 6, 8
- Hardy technique for, 8–10
- Hirsch technique for, 1–2
- historical overview of, **1–10**
- sublabial, 94–99

Transzygomatic approach, to parasellar and
suprasellar lesions, 109–111

Tuberculosis, of pituitary, 71

Tumor(s), pituitary. *See* Pituitary tumors.

U

Urinary free cortisol test, in corticotroph
adenoma, 46

V

Vasopressin. *See* Antidiuretic hormone.

Visual disorders

- after pituitary radiotherapy, 162–163
- in prolactinoma, 29